The efficacy and safety of activated vitamin D for CKD-MBD

Nobuki Hayakawa, Atsushi Suzuki

研究成果: Article査読

抄録

Metabolic bone disorders that are represented by secondary hyperparathyroidism occur with the progression of chronic kidney disease(CKD). The administration of activated vitamin D is expected to improve high-turnover bone disorders and is widely used for the management of bone mineral diseases in patients with CKD and end-stage renal disease. CKD is an underlying disease of secondary osteoporosis and coexists with primary osteoporosis at a high rate. With regard to osteoporosis patients with renal insufficiency, the administration of activated vitamin D is also thought to reduce the fracture incidence by both increasing bone mass and reducing falls.

本文言語English
ページ(範囲)1333-1338
ページ数6
ジャーナルClinical calcium
26
9
出版ステータスPublished - 01-09-2016

All Science Journal Classification (ASJC) codes

  • 医学(全般)

フィンガープリント

「The efficacy and safety of activated vitamin D for CKD-MBD」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル